Invitae is not a company I would normally look at for a number of reasons - its stock price is falling, it's loosing money, and there's no dividend. But it's a genetic testing company pushing the envelope on the number of genes it's testing for while dropping the price of the test incredibly fast. Drop that kind of corporate and academic intensity right in the middle of an exploding science like genomics and the financial and health benefits are astronomical.
Invitae is a genetic information company whose mission is to bring genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene tests today.
Invitae Corporation, a genetic information company, focuses on bringing comprehensive genetic information into mainstream medical practice to enhance the quality of healthcare. It processes DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for clinicians and their patients using an integrated portfolio of laboratory processes, software tools, and informatics capabilities. The company provides a diagnostic service comprising hundreds of genes for various genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas. It also offers solutions that enable sharing of genetic information consisting of Invitae Family History Tool, a Web or iPad application, which provides family history; and Clinvitae, a Web property that allows physicians or patients to look up individual genes and variants in order to find out additional genetic information. It operates in the United States, Canada, Israel, and internationally. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. The company was founded in 2010 and is headquartered in San Francisco, California. Invitae Corporation operates as a subsidiary of Locus Development Inc. (Summary) (Company) (Chart)
| 19 December 2016 Price $7.20 1yr Target $10.25 Analysts --- Dividend $--- Payout Ratio --- 1yr Cap Gain 42.36% Yield --- 1yr Tot Return 42.36% P/E --- PEG --- Beta --- | EPS (ttm) $-3.11 EPS next yr $-2.43 Forward P/E --- EPS next 5yr 8.00% 1yr Price Support $--- Market Cap $282.10 Mil Revenues $19.00 Mil Earnings $-99.80 Mil Profit Margin --- Quick Ratio 5.60 Current Ratio 5.60 Debt/Equity 0.21 | 1yr RevGR --- 3yr RevGR --- 5yr RevGR --- 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA -77.00% ROE -95.80% |
 |  |
My Opinion
Based upon an inspection of the fundamentals as well as the technicals, I can't find any basis in the type of investing I do that would justify buying any shares of this company. But there's something about this whole area of science that's intriging. And I want to be part of that excitement.
So I can't justify owning shares in this company by any stretch of the imagination but contrary to my own advice, I intend to start a position in this company in the very near future. If I live long enough I may live to regret this decision but it won't be the first time I did something dumb in the market and lost money. And it probably won't be my last time either.
Print 
PDF
RSS Feed
